Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia

Fig. 2

Survival outcomes in patients treated with UCB infusion as an adjuvant consolidation therapy. a Swimmer plot of dynamic response for patients following two cycles of UCB infusion treatment (n = 51). Each bar represents an individual patient with ELN risk group color-coded. Different symbols indicate different events, with MRD labeled at the time of UCB infusion and upon the status changed. b Kaplan-Meier curves of OS for patients treated with UCB infusion (n = 51). The median OS for UCB infusion was not reached (range, 9.3–100 months). c Kaplan-Meier curves of EFS for patients treated with UCB infusion (n = 51). The median EFS for UCB infusion was 72.2 months (range, 5.4–100 months)

Back to article page